Fulranumab |
| Catalog No.GC72341 |
Fulranumab est un anticorps monoclonal igg2 humain dirigé contre le facteur de croissance nerveuse (NGF) qui peut être utilisé dans la recherche sur la douleur.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 902141-80-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Fulranumab (200 μg/mL; 60 min) completely inhibits 10 ng/mL anti-fulranumab monkey polyclonal antibody, inhibits 100 and 1,000 ng/mL of anti-fulranumab antibody by over 90%[1].
Fulranumab (5-100 μg/mL) partially and dose dependently suppresses the false-positive anti-drug antibody (ADA) caused by acid pretreatment NGF[1].
References:
[1]. Dai S, et al. Development of a method that eliminates false-positive results due to nerve growth factor interference in the assessment of fulranumab immunogenicity. AAPS J. 2014 May;16(3):464-77.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *